CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We tested αPD-L1 and CD122-directed immunotherapy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632314/
https://www.ncbi.nlm.nih.gov/pubmed/34858732
http://dx.doi.org/10.1080/2162402X.2021.2006529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632314/
https://www.ncbi.nlm.nih.gov/pubmed/34858732
http://dx.doi.org/10.1080/2162402X.2021.2006529

Ejemplares similares